Another study evaluated durvalumab in combination with gefitinib in EGFR-mutant NSCLC, concluding that treatment was generally tolerable given a treatment discontinuation rate of 20% due to grade 3/4 toxicity (4/20 patients: increased ALT and/or AST in three, and pneumonitis in one). Here, EGFR is linked to non-small cell lung carcinoma.